Next-generation antibiotics for all.

GARDP is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By carrying out research and development and forging public-private partnerships, GARDP is ensuring that the right antibiotics are developed and reach the people who need them.

Highlights

FinancialTimes Thumbnail
Opinion

We need to test drugs on newborns despite the risks

Webinar ApprovalToAccess 20261027 Blank (1)
Events

Webinar – From approval to access: A new model for delivering effective antibiotics

ThaiFDA MediaCoverage Thumbnail
Media Coverage

Thai FDA approves NUZOLVENCE® (zoliflodacin) in July, just six months after US authorization

A global health crisis is unfolding.

Every 6 seconds, a life is lost to antimicrobial resistance.

Bacteria are evolving, and existing antibiotics are losing power, making once-treatable infections deadly again.

Antimicrobial resistance (AMR) threatens everyone, everywhere.

Home stats
100+

partners across 27 countries driving innovation and access.

Home stats
8

treatments in development targeting WHO priority pathogens.

Home stats
250,000+

pre-clinical compounds screened.

Home stats
5

in-licensing agreements.